

## **Prior Preterm Pregnancy Program**

To support your efforts in preventing preterm delivery in high-risk pregnant women, Amerigroup District of Columbia, Inc. is launching a program to ensure providers are aware of members who may benefit from administration of 17 alpha-hydroxyprogesterone caproate (17P). Through this program, you will receive an alert listing members on your panel identified through our high-risk screening survey as potential candidates for 17P.

If you wish to prescribe 17P for your patient, we offer the following guidance on how you may obtain 17P for delivery and administration:

- For office administration of 17P, no prior authorization (PA) is required:
  - Fax the prescription and a copy of the member's ID card to Accredo Specialty Pharmacy at 1-800-824-2642 or call in the prescription to 1-800-870-6419.
  - Accredo needs to know where to ship the medication. The member will be contacted by Accredo for verification of delivery before the medication is shipped.
  - If the member misses Accredo's call, please refer them to Accredo Customer Support at 1-800-870-6419.

Preterm birth (delivery before 37 weeks and zero/seven days of gestation) is a leading cause of infant morbidity and mortality in the United States. For women who have had a spontaneous preterm delivery, the risk for preterm delivery in subsequent pregnancies is 1.5-2 times higher. For pregnant women with a singleton pregnancy and a history of spontaneous preterm delivery, 17P can reduce the risk of preterm birth by approximately 30 percent. The U.S. Food and Drug Administration approved hydroxyprogesterone caproate injections to reduce the risk of preterm delivery in pregnant women with a history of prior preterm birth. As with any drug, there are risks that may outweigh these benefits.

If you have questions about this communication, please contact Provider Services at 1-800-454-3730 or an Amerigroup obstetric case manager at 1-800-600-4441.